NECN S/C Herceptin Reactions October 2014 Wendy Anderson Macmillan Nurse Consultant Chemotherapy STNHSFT Melanie Robertson Nurse Consultant Oncology CHS.

Slides:



Advertisements
Similar presentations
Utilization Patterns of Erythropoiesis Stimulating Agents Prescribed for Chemotherapy-Induced Anemia, and the Impact of the Outpatient Regimen on Subsequent.
Advertisements

NWLH NHS Trust Chemotherapy Lead Nurse/Matron
Oncologic Drugs Advisory Committee
©American Society of Clinical Oncology All rights reserved - American.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
Taxanes for Ovarian Cancer: Progress Report Rosemary Tate Information Projects Team December 2000.
Door to Needle Neutropenic Sepsis Audit (Macmillan Chemotherapy Unit ) May 11– October 11 Baleseng Nkolobe NWLH NHS Trust Chemotherapy Lead Nurse/Matron.
Improving the oncology patient’s journey within a Clinical Research Facility – using the National Chemotherapy Advisory Group (2009) Chemotherapy Pathway.
MEDICATION SAFETY: Clozapine Initiation Chart Review
Implementing a Cold Chain System Ensuring Cost Effectiveness and Reducing Unused Dispensed Chemotherapy Sue Hull Helen Wilkinson.
Acute Oncology Service (Insert relevant service name)
ACRIN 6657/CALGB Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.
Sunderland Neutropenic Sepsis Audit Melanie Robertson – Nurse Consultant Oncology.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
1 COMMUNITY CHEMOTHERAPY NICOLA CALLAM HARROW PRIMARY CARE TRUST MACMILLAN COMMUNITY CHEMOTHERAPY CLINICAL NURSE SPECIALIST.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.
Our Service in 10 Mins Claire Ikwan-McCabe Acute Oncology Nurse Friday, 19th April 2013.
National Comparative Audit of Blood Transfusion National Blood Service National Comparative Audit of Overnight Red Blood Cell Transfusion Prepared by Tanya.
Clinical Research in a Community Practice Bob Behrens, MD Iowa Oncology Research Association (IORA)
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Title of Scholar Project Month day, year Presenter: Supervisor(s): Critical Care Western.
AIM Statement The use of reminders to eligible patients in the Resident Clinic to have a mammogram will improve rates of screening. Over a 6 month period,
MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
NECN Colorectal NSSG Audit of Waiting Times for Lower GI Cancer Patients in NECN April 2010 – March 2011.
TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.
APHON Pediatric Chemotherapy and Biotherapy for Non- Cancer Diseases.
EPMA- Learning from Serious Incidents STAT dosing Iain Davidson Chief Pharmacist Feb 16.
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
Improving Outcomes in Lung Cancer Project - ILCOP Jeanette Draffan Macmillan Lung CNS NCLFN representative ILCOP.
Standards and Competencies for Cancer Chemotherapy Nursing Practice in Canada: CANO/ACIO AN INTRODUCTION.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
PATIENT SELF- ADMINISTRATION OF MEDICATION PURPOSE / POLICY Purpose: To promote correct administration of meds by patients and families/caregivers Policy:
JUST GIVE IT: a 2 phase study to audit the Immediate Management of Patients with Proven or Suspected Neutropenic Sepsis by Ally Gruber Acute Oncology Clinical.
An Audit of Hip Fracture Analgesia at Darent Valley Hospital Dr D Neely, Dr M Kanagarathnam, Dr M Satisha Department of Anaesthetics, Darent Valley Hospital,
Tracheostomy Audit Clinical Audit DepartmentNovember 2011 Head and Neck Airways Team.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
The Lung Defence Home IV Antibiotic and Ambulatory Care Service Karen Henderson Clinical Nurse Specialist.
Re-audit of Microvascular Free Flap Monitoring Clinical Audit Department November 2011 Head and Neck Practice Development Unit.
H Aladin1, A Tameem2, M Rushton3, E Roe3, A Jennings4
Management of Paracetamol Overdose - Closing the loop in the audit cycle part of the National Audit coordinated by the College of Emergency Medicine Drs.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Teacher Evaluation Process
NICE Guidance – Service delivery for patients with Sarcomas
Duration of Therapy of Colony Stimulating Factors in Oncology
Controlling Measuring Quality of Patient Care
What component is the greatest barrier for you as an evaluator?
FRACTURED NECK OF FEMUR
New Drug Capacity Calculator
Pathway for patients with suspected Breast Cancer
Clinical audit 2017/18 National Results
Introduction The use of trastuzumab in the (neo)adjuvant setting for patients with her-2 positive early breast cancer is known to reduce the rate of disease.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Clinical audit 2017/18 National Results
The Development of an Innovative Nurse-Led Ovarian Cancer Survivorship Clinic Sarah Burton Macmillan Clinical nurse specialist, Clare Churcher Clinical.
The Development of an Innovative Nurse-Led Ovarian Cancer Survivorship Clinic Sarah Burton Macmillan Clinical nurse specialist, Clare Churcher Clinical.
UK IT Industry Awards – UK Public Sector Project of the Year
2018 National Mesothelioma Audit
FRACTURED NECK OF FEMUR
Our goals in using DAWN MPD software in our nurse-led clinic -
Antimicrobial ward round
Pathway for patients with suspected Breast Cancer
A single centre experience of febrile neutropenia rates in long acting compared with short acting GCSF preparations in breast cancer patients Dr Rebecca.
Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:
Percentage of patients who had their pre-evening capillary blood glucose monitored at least once during their steroid therapy. Percentage of patients who.
Problem/ Purpose Statement
Glucose levels must be monitored in patients receiving steroids for immunotherapy-related toxicity Title: Subtitle Risk Assessment of Hyperglycaemia Induced.
Presentation transcript:

NECN S/C Herceptin Reactions October 2014 Wendy Anderson Macmillan Nurse Consultant Chemotherapy STNHSFT Melanie Robertson Nurse Consultant Oncology CHS

Background IV Herceptin administration requires – 6 hours observation post first cycle – 2 hours observation post subsequent cycles Network protocol for IV Herceptin administration requires – 6 hours observation post first cycle – 2 hours observation post second cycle – Subsequent treatments no observation S/C Herceptin licence recommends observation as per IV Local experience within SafeHer clinical trial suggested observation may not be required.

Objectives Monitor the number of patients without administration reactions to S/C Herceptin To specify reactions that were observed or patient reported Report the type severity and timing of any observed reactions Make recommendations re observation requirements following S/C Herceptin administration

Method All NECN cancer centres and units were invited to participate in audit Seven out of nine Trust submitted patient details to the Network Information was collected retrospectively on previous administered cycles

Audit sample 110 number patients received S/C Herceptin 618 doses (at least) of S/C Herceptin were administered in total 87% received S/C Herceptin as single agent 13% received S/C Herceptin concurrently with chemotherapy 78% received S/C Herceptin as adjuvant treatment

Results

Treatment intent

Treatment type

Reactions Of the 618 treatments given to 110 patients – 3 patient reactions were seen – 2.7% of patients had a reaction to S/C Herceptin – Reactions were seen in 0.4% of overall treatments administered. The audit had expected to document what proportion of patients were observed for the required time period but unfortunately failed to do so.

Reactions Of 110 patients and 618 doses given 3 patients had an observed reaction no patients self reported a reaction Reactions as below Subsequent management – Reaction 1 subsequent treatment given IV – Reaction 2 Continued without intervention – Reaction 3 subsequent treatment given with Paracetamol and Chlorampheniramine pre meds ReactionCycleReaction TypeReaction type Other please stateSeverityDrugsReaction time 13RashblisteringpainSeverenonduring admin 29Rasherythema Mildnon2 hours 31FeverfeverdizzinessmoderateParacetamol3 mins

Recommendations NECN Chemotherapy group to consider the following options regarding observation schedule post S/C Herceptin administration Option1 - Observe in accordance with licence Option 2 – Observe as per current NECN guidelines (6 hrs first treatment, 2hrs second) Option 3 – No observation recommended